79 related articles for article (PubMed ID: 34224180)
1. Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Passamonti F; Gupta V; Martino B; Foltz L; Zaritskey A; Al-Ali HK; Tavares R; Maffioli M; Raanani P; Giraldo P; Griesshammer M; Guglielmelli P; Bouard C; Paley C; Tiwari R; Vannucchi AM
Hematol Oncol; 2021 Oct; 39(4):558-566. PubMed ID: 34224180
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study.
Talpaz M; Erickson-Viitanen S; Hou K; Hamburg S; Baer MR
J Hematol Oncol; 2018 Aug; 11(1):101. PubMed ID: 30086777
[TBL] [Abstract][Full Text] [Related]
3. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Talpaz M; Paquette R; Afrin L; Hamburg SI; Prchal JT; Jamieson K; Terebelo HR; Ortega GL; Lyons RM; Tiu RV; Winton EF; Natrajan K; Odenike O; Claxton D; Peng W; O'Neill P; Erickson-Viitanen S; Leopold L; Sandor V; Levy RS; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2013 Oct; 6(1):81. PubMed ID: 24283202
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Vaddi K; Erickson-Viitanen S; Sun W; Sandor V; Kantarjian HM
Haematologica; 2013 Dec; 98(12):1865-71. PubMed ID: 24038026
[TBL] [Abstract][Full Text] [Related]
5. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Mascarenhas J; Kremyanskaya M; Patriarca A; Palandri F; Devos T; Passamonti F; Rampal RK; Mead AJ; Hobbs G; Scandura JM; Talpaz M; Granacher N; Somervaille TCP; Hoffman R; Wondergem MJ; Salama ME; Colak G; Cui J; Kiladjian JJ; Vannucchi AM; Verstovsek S; Curto-García N; Harrison C; Gupta V
J Clin Oncol; 2023 Nov; 41(32):4993-5004. PubMed ID: 36881782
[TBL] [Abstract][Full Text] [Related]
6. A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Tavares R; Souza CA; Paley C; Bouard C; Tiwari R; Pasquini R
Hematol Transfus Cell Ther; 2020; 42(1):46-53. PubMed ID: 31235325
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial.
Gupta V; Yacoub A; Mesa RA; Harrison CN; Vannucchi AM; Kiladjian JJ; Deeg HJ; Fazal S; Foltz L; Mattison RJ; Miller CB; Parameswaran V; Brown P; Hernandez C; Wang J; Talpaz M
Leuk Lymphoma; 2024 Jun; ():1-11. PubMed ID: 38838026
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT; Harrison CN; Kiladjian JJ; Mesa R; Vannucchi AM; Komrokji RS; Bose P; Kremyanskaya M; Mead A; Gotlib J; Rose S; Sanabria F; Marsousi N; Giuseppi AC; Jiang H; Palmer JM; McCaul K; Ribrag V; Passamonti F
Blood Adv; 2024 May; ():. PubMed ID: 38820422
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
Zhang Y; Zhou H; Jiang Z; Wu D; Zhuang J; Li W; Jiang Q; Wang X; Huang J; Zhu H; Yang L; Du X; Li F; Xia R; Zhang F; Hu J; Li Y; Hu Y; Liu J; Jin C; Sun K; Zhou Z; Wu L; Yin H; Suo S; Yu W; Jin J
Am J Hematol; 2024 Apr; 99(4):774-779. PubMed ID: 38343062
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Sureau L; Orvain C; Ianotto JC; Ugo V; Kiladjian JJ; Luque Paz D; Riou J
Blood Cancer J; 2021 Jul; 11(7):135. PubMed ID: 34315858
[TBL] [Abstract][Full Text] [Related]
11. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
[TBL] [Abstract][Full Text] [Related]
12. Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
Loscocco GG; Guglielmelli P; Gangat N; Rossi E; Mannarelli C; Betti S; Maccari C; Ramundo F; Jadoon Y; Gesullo F; Ceglie S; Paoli C; Pardanani A; De Stefano V; Tefferi A; Vannucchi AM
Am J Hematol; 2021 Nov; 96(11):1472-1480. PubMed ID: 34424575
[TBL] [Abstract][Full Text] [Related]
13. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
14. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Bose P; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):641-649. PubMed ID: 34272171
[TBL] [Abstract][Full Text] [Related]
15. Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.
Stein BL
Curr Hematol Malig Rep; 2021 Oct; 16(5):483-489. PubMed ID: 34499329
[TBL] [Abstract][Full Text] [Related]
16. Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Cervantes F; Ross DM; Radinoff A; Palandri F; Myasnikov A; Vannucchi AM; Zachee P; Gisslinger H; Komatsu N; Foltz L; Mannelli F; Passamonti F; Gilotti G; Sadek I; Tiwari R; Zor E; Al-Ali HK
Leukemia; 2021 Dec; 35(12):3626. PubMed ID: 34475521
[No Abstract] [Full Text] [Related]
17. The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Neubauer A; Johow J; Mack E; Burchert A; Meyn D; Kadlubiec A; Torje I; Wulf H; Vogelmeier CF; Hoyer J; Skevaki C; Muellenbach RM; Keller C; Schade-Brittinger C; Rolfes C; Wiesmann T
Leukemia; 2021 Oct; 35(10):2917-2923. PubMed ID: 34385593
[TBL] [Abstract][Full Text] [Related]
18. Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies.
Melillo N; Dickinson J; Tan L; Mistry HB; Huber HJ
Front Pharmacol; 2023; 14():1272058. PubMed ID: 37900154
[TBL] [Abstract][Full Text] [Related]
19. Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study.
Palandri F; Al-Ali HK; Guglielmelli P; Zuurman MW; Sarkar R; Gupta V
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345196
[TBL] [Abstract][Full Text] [Related]
20. Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
Verstovsek S; Parasuraman S; Yu J; Shah A; Kumar S; Xi A; Harrison C
Ann Hematol; 2022 Jan; 101(1):131-137. PubMed ID: 34625831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
